Achillion Pharmaceuticals, Inc. Sued by Investors After Stock Drops 58% on Announcement that Clinical Hold of Drug Sovaprevir

  Achillion Pharmaceuticals, Inc. Sued by Investors After Stock Drops 58% on
       Announcement that Clinical Hold of Drug Sovaprevir Will Continue

PR Newswire

SAN DIEGO and NEW HAVEN, Conn., Oct. 14, 2013

SAN DIEGO andNEW HAVEN, Conn., Oct. 14, 2013 /PRNewswire/ --Shareholder
rights law firm Robbins Arroyo LLP announces that an investor of Achillion
Pharmaceuticals, Inc. (NASDAQ: ACHN) has filed a federal securities fraud
class action complaint in the U.S. District Court, District of Connecticut.
The complaint alleges that the company and certain of its officers violated
the Securities and Exchange Act of 1934 between April 21, 2012 and September
27, 2013 (the "Class Period"). 

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Learn more about our investigation on our Shareholder Rights Blog:
http://www.robbinsarroyo.com/shareholders-rights-blog/achillion-pharmaceuticals-inc/

Achillion Accused of Misleading Investors Regarding Viability of Sovaprevir 

Shares of Achillion fell $4.22 per share, or more than 58%, on September 27,
2013, after the company disclosed that the U.S. Food and Drug Administration
("FDA") continued its clinical hold on sovaprevir, its premier investigative
drug for the treatment of hepatitis. This steep decline comes just two months
after Achillion experienced an initial 25% decline per share on the
announcement that the FDA instituted the clinical hold on July 1, 2013.

According to the complaint, defendants made false and/or misleading statements
and failed to disclose material adverse facts about the company's business,
operations, and prospects, including the safety and suitability of sovaprevir.
Defendants failed to inform investors that sovaprevir did not interact well
with other drugs commonly administered to treat hepatitis and/or HIV, and
misled investors to believe that even though patients in the company's
clinical trials for sovaprevir had elevations in liver enzymes, that these
liver enzymes elevations were transient and returned to baseline values and
were attributable to non-drug-related factors.

If you invested in Achillion and would like to discuss your shareholder rights
please contact attorney Darnell R. Donahue at (800) 350-6003,
DDonahue@robbinsarroyo.com, or via the shareholder information form on the
firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation
and shareholder rights law. The firm represents individual and institutional
investors in shareholder derivative and securities class action lawsuits, and
has helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. For more information, please
go to http://www.robbinsarroyo.com.

Attorney Advertising.Past results do not guarantee a similar outcome.

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

SOURCE Robbins Arroyo LLP

Website: http://robbinsumeda.com
 
Press spacebar to pause and continue. Press esc to stop.